JPRN-UMIN000006428招募中2 期
Phase II study of FEC followed by Nab-paclitaxel as Neoadjuvant Chemotherapy for Primary Breast Cancer - Phase II study of FEC followed by Nab-paclitaxel as Neoadjuvant Chemotherapy for Primary Breast Cancer
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1.Inflammatory and bilateral breast cancer 2.Active another cancer 3.History of hypersensitivity reaction 4. Other severe complications, such as pulmonary emphysema or pulmonary fibrosis, uncontrollable diabetes, heart failure, renal insufficiency, liver failure 5. Contraindication to the study drugs 6. Has active infection or fever which suspected of infection 7.During administration of flucytosine, phenytoin, warfarin potassium 8.Physician judged improper to entry this trial
研究者
相似试验
招募中
2 期
Phase II study of FEC followed by Nab-paclitaxel as Neoadjuvant Chemotherapy for Primary Breast CancerBreast cancerJPRN-UMIN000009152Toho University Omori Medical Center40
已完成
2 期
Phase II study of Nab-paclitaxel followed by FEC as neoadjuvant chemotherapy for the operable breast cancerbreast cancerJPRN-UMIN000011048Kitasato University Kitasato Institute Hospital20
已完成
2 期
A phase 2 study of nab-Paclitaxel followed by FEC (Fluorouracil, Epirubicin, Cyclophosphamide) as primary therapy for operable breast cancerBreast CancerJPRN-UMIN000009733Hiroshima city hospital40
已完成
2 期
Phase II study of EC followed by Nab-paclitaxel as Neoadjuvant Chemotherapy for Early Breast Cancerbreast cancerJPRN-UMIN000006020Tokai University School of Medicine50
招募中
2 期
Phase II study of EC followed by Nab-paclitaxel as neoadjuvant chemotherapy for HER2 negative with lymph node metastasesbreast cancerJPRN-UMIN000010685Saitama Medical Center,Saitama Medical University40